Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHA:603707)
7.89
-0.01 (-0.13%)
Sep 4, 2026, 3:00 PM CST
SHA:603707 Revenue
Nanjing King-Friend Biochemical Pharmaceutical had revenue of 997.60M CNY in the quarter ending June 30, 2026, a decrease of -8.86%. This brings the company's revenue in the last twelve months to 3.94B, up 4.69% year-over-year. In the year 2025, Nanjing King-Friend Biochemical Pharmaceutical had annual revenue of 3.99B with 1.71% growth.
Revenue (ttm)
3.94B
Revenue Growth
+4.69%
P/S Ratio
3.24
Revenue / Employee
2.53M
Employees
1,558
Market Cap
12.74B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.99B | 67.09M | 1.71% |
| Dec 31, 2024 | 3.92B | -7.80M | -0.20% |
| Dec 31, 2023 | 3.93B | 218.67M | 5.89% |
| Dec 31, 2022 | 3.71B | 26.03M | 0.71% |
| Dec 31, 2021 | 3.69B | 771.81M | 26.48% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Zhejiang Hisun Pharmaceutical | 9.77B |
| Zhejiang Medicine | 8.94B |
| Shanghai Shyndec Pharmaceutical | 8.43B |
| Zhejiang CONBA Pharmaceutical | 6.82B |
| Guobang Pharma | 6.13B |
| Shenzhen Hepalink Pharmaceutical Group | 5.24B |
| Zhejiang Jiuzhou Pharmaceutical | 5.21B |
| Tibet Rhodiola Pharmaceutical Holding Co. | 2.89B |